BOXED O
WARNING O
: O
WARNING O
: O
XELODA-WARFARIN O
INTERACTION O
WARNING O
: O
XELODA-WARFARIN O
INTERACTION O
XELODA O
Warfarin O
Interaction O
: O
Patients O
receiving O
concomitant O
capecitabine O
and O
oral O
coumarin-derivative O
anticoagulant O
therapy O
should O
have O
their O
anticoagulant O
response O
( O
INR O
or O
prothrombin O
time O
) O
monitored O
frequently O
in O
order O
to O
adjust O
the O
anticoagulant O
dose O
accordingly O
. O

A O
clinically O
important O
XELODA-Warfarin O
drug O
interaction O
was O
demonstrated O
in O
a O
clinical O
pharmacology O
trial O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
and O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

Altered B-NonOSE_AE
coagulation I-NonOSE_AE
parameters I-NonOSE_AE
and/or O
bleeding B-NonOSE_AE
, O
including O
death B-NonOSE_AE
, O
have O
been O
reported O
in O
patients O
taking O
XELODA O
concomitantly O
with O
coumarin-derivative O
anticoagulants O
such O
as O
warfarin O
and O
phenprocoumon O
. O

Postmarketing O
reports O
have O
shown O
clinically O
significant O
increases B-NonOSE_AE
in I-NonOSE_AE
prothrombin I-NonOSE_AE
time I-NonOSE_AE
( O
PT O
) O
and O
INR O
in O
patients O
who O
were O
stabilized O
on O
anticoagulants O
at O
the O
time O
XELODA O
was O
introduced O
. O

These O
events O
occurred O
within O
several O
days O
and O
up O
to O
several O
months O
after O
initiating O
XELODA O
therapy O
and O
, O
in O
a O
few O
cases O
, O
within O
1 O
month O
after O
stopping O
XELODA O
. O

These O
events O
occurred O
in O
patients O
with O
and O
without O
liver B-Not_AE_Candidate
metastases I-Not_AE_Candidate
. O

Age O
greater O
than O
60 O
and O
a O
diagnosis O
of O
cancer B-Not_AE_Candidate
independently O
predispose O
patients O
to O
an O
increased O
risk O
of O
coagulopathy B-NonOSE_AE
. O

EXCERPT O
: O
WARNING O
: O
XELODA-WARFARIN O
INTERACTION O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

Patients O
receiving O
concomitant O
XELODA O
and O
oral O
coumarin-derivative O
anticoagulants O
such O
as O
warfarin O
and O
phenprocoumon O
should O
have O
their O
anticoagulant O
response O
( O
INR O
or O
prothrombin O
time O
) O
monitored O
frequently O
in O
order O
to O
adjust O
the O
anticoagulant O
dose O
accordingly O
. O

Altered O
coagulation O
parameters O
and/or O
bleeding O
, O
including O
death O
, O
have O
been O
reported O
during O
concomitant O
use O
. O

* O
Occurrence O
: O
Within O
several O
days O
and O
up O
to O
several O
months O
after O
initiating O
XELODA O
therapy O
; O
may O
also O
be O
seen O
within O
1 O
month O
after O
stopping O
XELODA O
* O
Predisposing O
factors O
: O
age O
> O
60 O
and O
diagnosis O
of O
cancer O

